06:15 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million on Aug. 8 in its series B and C rounds. The company closed its series B round with $15 million led by...
17:49 , Aug 8, 2018 |  BC Extra  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million in its series B and C rounds. The company closed its series B round with $15 million led by Decheng Capital, while...
20:06 , May 18, 2018 |  BioCentury  |  Finance

Ansun’s China ambitions

The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market. Sinopharm Healthcare Fund and Lilly Asia Ventures led the round, with...
02:29 , May 18, 2018 |  BC Week In Review  |  Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised on May 14 a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China,...
15:02 , May 14, 2018 |  BC Extra  |  Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital,...
00:21 , Apr 29, 2017 |  BioCentury  |  Finance

Building bispecifics

Encouraging preclinical data and a broadly applicable bispecifics platform helped Shanghai-based EpimAb Biotherapeutics Inc. attract $25 million in series A funding from a syndicate of Chinese, U.S. and U.K. investors. "Most biologics companies in China...
21:10 , Apr 27, 2017 |  BC Week In Review  |  Financial News

EpimAb completes venture financing

On April 25, bi-specific antibody company EpimAb Biotherapeutics Inc. (Shanghai, China) raised $25 million in a series A round led by Oriza Seed Capital. Also participating were Decheng Capital, 3E Bioventures Capital and Trend Investment...
04:33 , Apr 25, 2017 |  BC Extra  |  Financial News

EpimAb raises $25M in series A

EpimAb Biotherapeutics Inc. (Shanghai, China) raised $25 million in a series A round led by Oriza Seed Capital. Also participating were Decheng Capital, 3E Bioventures Capital and Trend Investment Group. EpimAb is developing bispecific antibodies for...
16:14 , Jan 13, 2017 |  BC Week In Review  |  Financial News

OncoImmune completes venture financing

OncoImmune raised $15 million in a series A round led by 3E Bioventures Capital. OncoImmune Inc., Rockville, Md.  ...
00:14 , Jan 13, 2017 |  BC Extra  |  Financial News

OncoImmune raises $15M in series A

OncoImmune Inc. (Rockville, Md.) said it raised $15 million in a series A round led by 3E Bioventures Capital. The company's lead candidate, CD24Fc, is in a Phase II study to prevent graft versus host...